The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
2019 · Cancer Discovery · 1,249 citations
https://doi.org/10.1158/2159-8290.cd-19-1167
D
David M. Briere
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
193
Papers
4.4K
Citations
17
h-index
21
i10-index
David M. Briere is an academic researcher from Bristol-Myers Squibb (Germany). The author has contributed to research in topics: Cancer-related gene regulation & Prostate Cancer Treatment and Research & Biochemical and Molecular Research. The author has an h-index of 17, co-authored 165 publications.
ORCID: 0009-0006-3868-0859Papers by this author
worksIdentification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor
2021 · Journal of Medicinal Chemistry · 644 citations
https://doi.org/10.1021/acs.jmedchem.1c01688
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
2022 · Nature Medicine · 465 citations
https://doi.org/10.1038/s41591-022-02007-7
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction
2022 · Journal of Medicinal Chemistry · 87 citations
https://doi.org/10.1021/acs.jmedchem.2c00741
Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
2025 · Clinical Cancer Research · 14 citations
https://doi.org/10.1158/1078-0432.ccr-24-2310
Supplementary Figure S7 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
2024 · 0 citations
https://doi.org/10.1158/2159-8290.27026171
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat